MeiraGTx PLC (MGTX): Debt to Book Capitalization Ratio

MeiraGTx Holdings - graphic logo of issuer MGTX

MeiraGTx Holdings plc (MGTX) specializes in developing treatments for orphan diseases, leveraging its own viral vector synthesis capacities. This approach reduces costs and accelerates product launches. The price action, where the indicator stands at 0.51, clearly demonstrates market expectations regarding large-scale capital investments in manufacturing plants. However, the business is currently facing a liquidity shortage due to costly testing phases in the absence of profit.

MeiraGTx Corp - MGTX Debts to Book Value (period 07/04/2022 - 10/31/2026)
Original product of MeiraGTx Holdings

This ratio determines the proportion of borrowed funds relative to equity, allowing investors to differentiate systemic financial risks from short-term volatility via the company's total debt-to-book capital level. The stability of this metric is critically important for MeiraGTx Holdings plc (MGTX), as high debt sustainability provides the necessary resources to develop their unique advancements in gene therapy and gene expression.

Main competitors

Debts to Book Capitalization TEM (Tempus AI Inc)|Debts to Book Capitalization qiagen.com QGEN|IONS - Debt to Book Capitalization Ratio|Repligen Corp (RGEN) - Debt to Book Value|RNA: Debts to Book Capitalization|Debts to Book Value CRISPR (CRSP)|WGS (GeneDx Holdings Corp.) - Debts to Book Capitalization|ultragenyx.com (RARE) - Debts to Net Assets|Debt to Book Capitalization Ratio Beam Therapeutics (BEAM)|SRPT (Sarepta Therapeutics) - Debt to Net Assets Ratio|Debts to Book Capitalization TWST (Twist Bio)|Debts to Book Capitalization 10x TXG|Intellia Therapeutics - Debts to Book Capitalization|Debt to Net Assets stoketherapeutics.com (STOK)|BLFS (BioLife Solutions) - Debt to Book Value|WVE: Debt to Book Capital|Debt to Book Value MAZE|Debt to Book Value Ratio SION (Sionna Corp)|Debt to Book Value PRME (Prime Medicine, Inc.)|TSHA (tayshagtx.com) - Debt to Net Assets Ratio|Debts to Book Capitalization QURE (uniQure)|Debt to Net Assets Ratio RGNX|SLDB - Debt to Book Capitalization Ratio|Debts to Book Value Ocugen Pharma|Pacific Biosciences (PACB) - Debt to Book Capitalization Ratio|BNTC (benitec.com) - Debt to Book Capitalization Ratio|DSGN (Design Therapeutics, Inc.) - Debts to Book Capitalization|Debt to Book Value Ratio RCKT (Rocket Pharma)|Debts to Book Capitalization FDMT|Debts to Net Assets lexeotx.com|Debt to Book Capitalization Ratio Korro Bio KRRO|EDIT: Debt to Book Value Ratio|Silence Therapeutics plc - Debts to Book Capitalization|Debt to Net Assets ProQR Therapeutics N.V. (PRQR)|codexis.com (CDXS) - Debt to Book Capitalization Ratio|SGMO - Debts to Net Assets|Debt to Book Value NAUT|MGX: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Precision BioSciences, Inc. (DTIL)|GBIO: Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio Boundless Bio, Inc BOLD|Exicure Inc. - Debt to Book Capitalization Ratio|Celsion Corporation - Debts to Book Capitalization|Phio Pharmaceuticals (PHIO) - Debt to Book Value|mustangbio.com (MBIO) - Debt to Book Capitalization Ratio|Debt to Book Value TransCode Therapeutics, Inc.|BNGO (Bionano Genomics Inc.) - Debts to Book Capitalization|APDN - Debt to Net Assets|Debt to Book Value BLUE (bluebird bio, Inc.)|Debt to Book Capital IPA|Omega Therapeutics, Inc. - Debt to Book Value|OMIC: Debt to Book Value Ratio|Regulus Therapeutics Inc - Debts to Book Capitalization|SYRS (Syros Pharmaceuticals, Inc) - Debt to Book Value Ratio|Telesis Bio, Inc. (TBIO) - Debt to Book Capitalization Ratio|Debt to Book Value Ratio TCON|UBX (Unity Biotechnology, Inc.) - Debts to Book Capitalization